ArticleCancer science2026
Targeting Wnt/β-Catenin Pathway by DNA Alkylating Pyrrole-Imidazole Polyamide in Colon Cancer.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Wnt/β-catenin pathway, which is under the control of T cell factor/lymphocyte enhancer factor (TCF/LEF) transcription factors, plays a pivotal role during carcinogenesis through the regulation of cancer cell proliferation and differentiation. Thus, it is likely that an inhibitor against this pro-oncogenic pathway might be a promising anti-cancer drug candidate. In the present study, we have synthesized a novel polyamide (WNT-Chb) composed of N-methylpyrrole, N-methylimidazole, and DNA alkylator chlorambucil, and examined its anti-cancer effect on colon cancer cells in vitro and in vivo. Based on our results, WNT-Chb preferentially bound to a consensus TCF/LEF-responsive element (5'-CCTTTGA-3'), and suppressed multiple Wnt-target gene expression. Consistent with these results, WNT-Chb attenuated in vitro proliferation and in vivo tumor growth of colon cancer cells with an aberrantly activated Wnt/β-catenin pathway. Together, these findings strongly suggest that the originally produced WNT-Chb might be a novel anti-cancer drug candidate against Wnt/β-catenin pathway-dependent colon cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.